The third part in our series of articles on investing in Life Science companies deals with regulatory issues. Regulatory processes are demanding and time-consuming, and failure to comply can be disastrous for a drug development company.

We are discontinuing our coverage of Mendus as the company has terminated the equity research agreement. Consequently, we will no longer be giving a target price (was SEK 14) or a recommendation (was Accumulate) for the stock.

In Q3, Mendus reported bringing ilixadencel back into clinical development, opening research centers for the CADENCE trial and progressing in building Phase III readiness.